{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:46:45Z","timestamp":1790837205144,"version":"4.1.0"},"reference-count":306,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009687","name":"Wroclaw Medical University","doi-asserted-by":"publisher","award":["STM.D090.20.122"],"award-info":[{"award-number":["STM.D090.20.122"]}],"id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Hematological malignancies, also referred to as blood cancers, are a group of diseases involving abnormal cell growth and persisting in the blood, lymph nodes, or bone marrow. The development of new targeted therapies including small molecule inhibitors, monoclonal antibodies, bispecific T cell engagers, antibody-drug conjugates, recombinant immunotoxins, and, finally, Chimeric Antigen Receptor T (CAR-T) cells has improved the clinical outcomes for blood cancers. In this review, we summarized 52 drugs that were divided into small molecule and macromolecule agents, approved by the Food and Drug Administration (FDA) in the period between 2011 and 2021 for the treatment of hematological malignancies. Forty of them have also been approved by the European Medicines Agency (EMA). We analyzed the FDA-approved drugs by investigating both their structures and mechanisms of action. It should be emphasized that the number of targeted drugs was significantly higher (46 drugs) than chemotherapy agents (6 drugs). We highlight recent advances in the design of drugs that are used to treat hematological malignancies, which make them more effective and less toxic.<\/jats:p>","DOI":"10.3390\/cancers14010087","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T08:38:46Z","timestamp":1640335126000},"page":"87","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["FDA-Approved Drugs for Hematological Malignancies\u2014The Last Decade Review"],"prefix":"10.3390","volume":"14","author":[{"given":"Aleksandra","family":"Sochacka-\u0106wik\u0142a","sequence":"first","affiliation":[{"name":"Department of Organic Chemistry and Drug Technology, Faculty of Pharmacy, Wroclaw Medical University, 211A Borowska Street, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6110-344X","authenticated-orcid":false,"given":"Marcin","family":"M\u0105czy\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry and Drug Technology, Faculty of Pharmacy, Wroclaw Medical University, 211A Borowska Street, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5806-0001","authenticated-orcid":false,"given":"Andrzej","family":"Regiec","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry and Drug Technology, Faculty of Pharmacy, Wroclaw Medical University, 211A Borowska Street, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1039\/D0BM00129E","article-title":"Nanomedicine\u2014A promising therapy for hematological malignancies","volume":"8","author":"Huang","year":"2020","journal-title":"Biomater Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.talanta.2011.08.034","article-title":"Analysis of anticancer drugs: A review","volume":"85","author":"Nussbaumer","year":"2011","journal-title":"Talanta"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jama.1946.02870380008004","article-title":"Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin\u2019s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders","volume":"132","author":"Goodman","year":"1946","journal-title":"J. Am. Med. Assoc."},{"key":"ref_4","unstructured":"(2021, August 23). Mustargen NDA #006695\u2014Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=006695."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-Aminopteroyl-glutamic acid (Aminopterin)","volume":"238","author":"Farber","year":"1948","journal-title":"N. Engl. J. Med."},{"key":"ref_6","unstructured":"(2021, August 23). Methotrexate Sodium NDA #008085\u2014Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=008085."},{"key":"ref_7","first-page":"211","article-title":"An evaluation of folic acid antagonists in adults with neoplastic diseases: A study of 93 patients with incurable neoplasms","volume":"43","author":"Wright","year":"1951","journal-title":"J. Natl. Med. Assoc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1021\/ja01122a037","article-title":"Studies on condensed pyrimidine systems. IX. The synthesis of some 6-substituted purines","volume":"74","author":"Elion","year":"1952","journal-title":"J. Am. Chem. Soc."},{"key":"ref_9","unstructured":"(2021, August 24). Purinethol NDA #009053\u2014Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=009053."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1021\/ja01573a087","article-title":"The synthesis of 5-fluoropyrimidines","volume":"79","author":"Dushinsky","year":"1957","journal-title":"J. Am. Chem. Soc."},{"key":"ref_11","unstructured":"(2021, August 24). Fluorouracil NDA 012209\u2014Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=012209."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jama.1960.03030130024007","article-title":"Chemotherapy of solid carcinoma","volume":"174","author":"Hurley","year":"1960","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1139\/o90-197","article-title":"The discovery of the vinca alkaloids\u2014Chemotherapeutic agents against cancer","volume":"68","author":"Noble","year":"1990","journal-title":"Biochem. Cell Biol."},{"key":"ref_14","unstructured":"(2021, August 25). Oncovin NDA #014103\u2014Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=014103."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41416-018-0300-x","article-title":"Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK","volume":"119","author":"Watson","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/BF01197761","article-title":"Antitumor antibiotics discovered and studied at the Institute of Microbial Chemistry","volume":"121","author":"Takeuchi","year":"1995","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1136\/bmj.3.5669.503","article-title":"Clinical evaluation of adriamycin, a new antitumour antibiotic","volume":"3","author":"Bonadonna","year":"1969","journal-title":"Br. Med. J."},{"key":"ref_18","unstructured":"(2021, August 25). Doxorubicin Hydrochloride NDA #050467\u2014Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=050467."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: Pharmacodynamics and adverse effects","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet. Genom."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/jlac.18450550206","article-title":"Ueber die einwirkung von ammoniak auf platinchlor\u00fc: Zweite abhandlung","volume":"55","author":"Peyrone","year":"1845","journal-title":"Ann. Chem. Pharm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/205698a0","article-title":"Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode","volume":"205","author":"Rosenberg","year":"1965","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"102925","DOI":"10.1016\/j.bioorg.2019.102925","article-title":"Cisplatin: The first metal based anticancer drug","volume":"88","author":"Ghosh","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1389201003379059","article-title":"Rituximab: The first monoclonal antibody approved for the treatment of lymphoma","volume":"1","author":"White","year":"2000","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_24","first-page":"935","article-title":"Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.2217\/fon-2020-0131","article-title":"Rituximab biosimilars in hematologic malignancies: The need for a real-world approach","volume":"16","author":"Shelbaya","year":"2020","journal-title":"Future Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Pottier, C., Fresnais, M., Gilon, M., J\u00e9rusalem, G., Longuesp\u00e9e, R., and Sounni, N.E. (2020). Tyrosine kinase inhibitors in cancer: Breakthrough and challenges of targeted therapy. Cancers, 12.","DOI":"10.3390\/cancers12030731"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7150\/ijms.1.101","article-title":"Tyrosine kinase\u2014Role and significance in cancer","volume":"1","author":"Paul","year":"2004","journal-title":"Int. J. Med. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.clinbiochem.2004.05.006","article-title":"Tyrosine kinase inhibitors in cancer therapy","volume":"37","author":"Madhusudan","year":"2004","journal-title":"Clin. Biochem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine kinases as targets for cancer therapy","volume":"353","author":"Krause","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_30","unstructured":"IMBRUVICA (Ibrutinib) (2021, October 19). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/205552s030,210563s006lblPI.pdf."},{"key":"ref_31","unstructured":"CALQUENCE (Acalabrutinib) (2021, October 19). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/210259s006s007lbl.pdf."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1200\/JCO.2012.44.4281","article-title":"Targeting B-Cell receptor signaling for anticancer therapy: The Bruton\u2019s tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies","volume":"31","author":"Wiestner","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"key":"ref_35","unstructured":"U.S. Food and Drug Administration (2021, December 22). FDA Grants Accelerated Approval to Bosutinib for Treatment of Newly-Diagnosed PH+ CML, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-bosutinib-treatment-newly-diagnosed-ph-cml."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1242\/jcs.175521","article-title":"Multifunctional Abl kinases in health and disease","volume":"129","author":"Khatri","year":"2016","journal-title":"J. Cell Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s12935-020-01518-y","article-title":"Ibrutinib in B-cell lymphoma: Single fighter might be enough?","volume":"20","author":"Xue","year":"2020","journal-title":"Cancer Cell Int."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40265-019-01252-4","article-title":"Zanubrutinib: First approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"ref_40","unstructured":"European Medicines Agency (2021, December 01). BRUKINSA (Zanubrutinib). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/19\/2167-public-summary-opinion-orphan-designation-zanubrutinib-treatment-lymphoplasmatic-lymphoma_en.pdf."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40265-017-0852-8","article-title":"Acalabrutinib: First global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"ref_42","unstructured":"European Medicines Agency (2021, December 01). CALQUENCE (Acalabrutinib). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/calquence-epar-medicine-overview_en.pdf."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-014-0178-8","article-title":"Ibrutinib: First global approval","volume":"74","author":"Cameron","year":"2014","journal-title":"Drugs"},{"key":"ref_44","unstructured":"European Medicines Agency (2021, December 01). IMBRUVICA (Ibrutinib). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/imbruvica-epar-medicine-overview_en.pdf."},{"key":"ref_45","unstructured":"(2021, October 25). Bosulif NDA #203341\u2014Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&varApplNo=203341."},{"key":"ref_46","unstructured":"BOSULIF (Bosutinib) (2021, September 07). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203341s009lbl.pdf."},{"key":"ref_47","unstructured":"European Medicines Agency (2021, December 01). BOSULIF (Bosutinib). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/bosulif-epar-medicine-overview_en.pdf."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","article-title":"Tyrosine kinase inhibitors: Multi-targeted or single-targeted?","volume":"2","author":"Broekman","year":"2011","journal-title":"World J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2174\/138955708786369591","article-title":"Recent advances in the development of multi-kinase inhibitors","volume":"8","author":"Krug","year":"2008","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/leu.2012.114","article-title":"Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia","volume":"26","author":"Swords","year":"2012","journal-title":"Leukemia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"595818","DOI":"10.3389\/fimmu.2020.595818","article-title":"Phosphoinositide 3-kinase signaling in the tumor microenvironment: What do we need to consider when treating chronic lymphocytic leukemia with PI3K inhibitors?","volume":"11","author":"Aydin","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"EPIC investigators. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: An international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1634\/theoncologist.2015-0253","article-title":"Ponatinib: Accelerated disapproval","volume":"20","author":"Gainor","year":"2015","journal-title":"Oncologist"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2016-10-745133","article-title":"Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor","volume":"129","author":"Lee","year":"2017","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s10637-017-0470-z","article-title":"Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia","volume":"35","author":"Mori","year":"2017","journal-title":"Investig. Drugs"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"10777","DOI":"10.2147\/CMAR.S212559","article-title":"Beyond Ruxolitinib: Fedratinib and other emergent treatment options for myelofibrosis","volume":"11","author":"Bewersdorf","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1038\/bcj.2015.63","article-title":"A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis","volume":"5","author":"Pardanani","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of Fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s40265-019-01205-x","article-title":"Fedratinib: First approval","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"ref_67","unstructured":"INREBIC (Fedratinib) (2021, December 05). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212327s000lbl.pdf."},{"key":"ref_68","unstructured":"European Medicines Agency (2021, December 01). INREBIC (Fedratinib). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/inrebic-epar-medicine-overview_en.pdf."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40265-019-1062-3","article-title":"Gilteritinib: First global approval","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"ref_70","unstructured":"European Medicines Agency (2021, December 01). XOSPATA (Gilteritinib). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/xospata-epar-medicine-overview_en.pdf."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40265-017-0779-0","article-title":"Midostaurin: First global approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"ref_72","unstructured":"European Medicines Agency (2021, December 02). RYDAPT (Midostaurin). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/rydapt-epar-summary-public_en.pdf."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4103\/CRST.CRST_98_19","article-title":"Ponatinib: A drug review","volume":"2","author":"Jain","year":"2019","journal-title":"Cancer Res. Stat. Treat."},{"key":"ref_74","unstructured":"European Medicines Agency (2021, December 02). ICLUSIG (Ponatinib). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/iclusig-epar-summary-public_en.pdf."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1158\/1078-0432.CCR-12-0653","article-title":"Food and Drug Administration approval: Ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis","volume":"18","author":"Deisseroth","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_76","unstructured":"European Medicines Agency (2021, December 02). JAKAVI (Ruxolitinib). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/jakavi-epar-summary-public_en.pdf."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1358\/dof.2007.032.06.1107995","article-title":"Phosphatidylinositol 3-kinase (PI3K) inhibitors as anticancer drugs","volume":"32","author":"Verheijen","year":"2007","journal-title":"Drugs Future"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.2174\/138161210791033950","article-title":"PI3K\/Akt signalling pathway specific inhibitors: A novel strategy to sensitize cancer cells to anti-cancer drugs","volume":"16","author":"Falasca","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/j.1349-7006.2008.00891.x","article-title":"Phosphatidylinositol 3-kinase inhibitors: Promising drug candidates for cancer therapy","volume":"99","author":"Kong","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_80","first-page":"157","article-title":"Zydelig (Idelalisib): First-in-class PI3 kinase inhibitor approved for the treatment of 3 hematologic malignancies","volume":"8","author":"Raedler","year":"2015","journal-title":"Am. Health Drug Benefits"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-12-0993-T","article-title":"BAY 80-6946 is a highly selective intravenous pI3K inhibitor with potent p110\u03b1 and p110\u03b4 activities in tumor cell lines and xenograft models","volume":"12","author":"Liu","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4, \u03b3, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.2147\/DDDT.S142406","article-title":"Copanlisib for treatment of B-cell malignancies: The development of a PI3K inhibitor with considerable differences to idelalisib","volume":"12","author":"Krause","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s40265-018-1013-4","article-title":"Duvelisib: First global approval","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"ref_85","unstructured":"European Medicines Agency (2021, December 02). COPIKTRA (Duvelisib). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/copiktra-epar-medicine-overview_en.pdf."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s40265-017-0838-6","article-title":"Copanlisib: First global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"ref_87","unstructured":"European Medicines Agency (2021, December 02). ALIQOPA (Copanlisib). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/18\/2064-public-summary-opinion-orphan-designation-copanlisib-treatment-marginal-zone-lymphoma_en.pdf."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s40265-014-0285-6","article-title":"Idelalisib: First global approval","volume":"74","author":"Markham","year":"2014","journal-title":"Drugs"},{"key":"ref_89","unstructured":"European Medicines Agency (2021, December 02). ZYDELIG (Idelalisib). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/zydelig-epar-medicine-overview_en.pdf."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Ganellin, C., Roberts, S., and Jefferis, R. (2013). Chapter 1\u2013Introduction to enzymes, receptors and the action of small molecule drugs. Introduction to Biological and Small Molecule Drug Research and Development, Elsevier.","DOI":"10.1016\/B978-0-12-397176-0.00001-7"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2009.02.019","article-title":"Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges","volume":"280","author":"Atadja","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","article-title":"FDA approval: Belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma","volume":"21","author":"Lee","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-15-0530","article-title":"Panobinostat for the treatment of multiple myeloma","volume":"21","author":"Laubach","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/14756366.2017.1417274","article-title":"Zinc binding groups for histone deacetylase inhibitors","volume":"33","author":"Zhang","year":"2018","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1038\/onc.2010.444","article-title":"Cancer-associated IDH mutations: Biomarker and therapeutic opportunities","volume":"29","author":"Yen","year":"2010","journal-title":"Oncogene"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/neuonc\/nov136","article-title":"Isocitrate dehydrogenase mutations in gliomas","volume":"18","author":"Waitkus","year":"2016","journal-title":"Neuro-Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fonc.2019.00417","article-title":"Mutant isocitrate dehydrogenase inhibitors as targeted cancer therapeutics","volume":"9","author":"Golub","year":"2019","journal-title":"Front Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/2040620718777467","article-title":"The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia","volume":"9","author":"DiNardo","year":"2018","journal-title":"Ther. Adv. Hematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1158\/1078-0432.CCR-18-3749","article-title":"FDA approval summary: Ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation","volume":"25","author":"Norsworthy","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"8073","DOI":"10.2147\/CMAR.S162784","article-title":"Enasidenib in acute myeloid leukemia: Clinical development and perspectives on treatment","volume":"11","author":"Reed","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","article-title":"Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response","volume":"130","author":"Amatangelo","year":"2017","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40364-018-0122-2","article-title":"Epigenetic regulation of cancer progression by EZH2: From biological insights to therapeutic potential","volume":"6","author":"Gan","year":"2018","journal-title":"Biomark. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: A first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood.V126.23.473.473","article-title":"Phase 1 study of Tazemetostat (EPZ-6438), an inhibitor of enhancer of Zeste-homolog 2 (EZH2): Preliminary safety and activity in relapsed or refractory non-hodgkin lymphoma (NHL) patients","volume":"126","author":"Ribrag","year":"2015","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: First approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"ref_107","unstructured":"TAZVERIK (Tazemetostat) (2021, September 14). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213400s000lbl.pdf."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrg.2017.80","article-title":"The DNA methyltransferase family: A versatile toolkit for epigenetic regulation","volume":"19","author":"Lyko","year":"2017","journal-title":"Nat. Rev. Genet."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1021\/acschembio.5b00781","article-title":"Structural chemistry of human RNA methyltransferases","volume":"11","author":"Schapira","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2165\/11209430-000000000-00000","article-title":"Azacitidine","volume":"72","author":"Keating","year":"2012","journal-title":"Drugs"},{"key":"ref_111","unstructured":"VIDAZA (Azacitidine for Injection) (2021, September 15). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050794s011lbl.pdf."},{"key":"ref_112","unstructured":"ONUREG (Azacitidine) (2021, September 15). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/214120s000lbl.pdf."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/leu.2008.145","article-title":"A pilot pharmacokinetic study of oral azacitidine","volume":"22","author":"Stoltz","year":"2008","journal-title":"Leukemia"},{"key":"ref_114","unstructured":"European Medicines Agency (2021, December 02). ONUREG (Azacitidine). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/onureg-epar-medicine-overview_en.pdf."},{"key":"ref_115","unstructured":"European Medicines Agency (2021, December 02). TAZVERIK (Tazemetostat). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/18\/2004-public-summary-opinion-orphan-designation-tazemetostat-treatment-diffuse-large-b-cell-lymphoma_en.pdf."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s40265-018-0978-3","article-title":"Ivosidenib: First global approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"ref_117","unstructured":"European Medicines Agency (2021, December 02). TIBSOVO (Ivosidenib). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-answers-withdrawal-marketing-authorisation-tibsovo-ivosidenib_en.pdf."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40265-017-0813-2","article-title":"Enasidenib: First global approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"ref_119","unstructured":"European Medicines Agency (2021, December 02). IDHIFA (Enasidenib). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_en.pdf."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40265-015-0388-8","article-title":"Panobinostat: First global approval","volume":"75","year":"2015","journal-title":"Drugs"},{"key":"ref_121","unstructured":"European Medicines Agency (2021, December 02). FARYDAK (Panobinostat). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/farydak-epar-summary-public_en.pdf."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40265-014-0275-8","article-title":"Belinostat: First global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"ref_123","unstructured":"European Medicines Agency (2021, December 02). BELEODAQ (Belinostat). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/12\/1055-public-summary-opinion-orphan-designation-belinostat-treatment-peripheral-t-cell-lymphoma-nodal\/disseminated_en.pdf."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tips.2009.03.007","article-title":"Mechanisms of Hedgehog pathway activation in cancer and implications for therapy","volume":"30","author":"Scales","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1038\/ncomms5355","article-title":"Structural basis for smoothened receptor modulation and chemoresistance to anticancer drugs","volume":"5","author":"Wang","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1158\/1078-0432.CCR-19-0365","article-title":"FDA approval summary: Glasdegib for newly diagnosed acute myeloid leukemia","volume":"25","author":"Norsworthy","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/14656566.2020.1713094","article-title":"An evaluation of glasdegib for the treatment of acute myelogenous leukemia","volume":"21","author":"Thomas","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40265-018-1047-7","article-title":"Glasdegib: First global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"ref_130","unstructured":"European Medicines Agency (2021, December 02). DAURISMO (Glasdegib). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/daurismo-epar-medicine-overview_en.pdf."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: Changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"12862","DOI":"10.18632\/oncotarget.3868","article-title":"New dimension in therapeutic targeting of BCL-2 family proteins","volume":"6","author":"Besbes","year":"2015","journal-title":"Oncotarget"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.exphem.2018.02.002","article-title":"Venetoclax: A new wave in hematooncology","volume":"61","author":"Mihalyova","year":"2018","journal-title":"Exp. Hematol."},{"key":"ref_134","unstructured":"VENCLEXTA (Venetoclax Tablets) (2021, September 17). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208573s009lbl.pdf."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","article-title":"First-in-class, first-in-human phase I study of Selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors","volume":"34","author":"Gabrail","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.2017.75.5207","article-title":"Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma","volume":"36","author":"Vogl","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_138","unstructured":"XPOVIO (Selinexor) (2021, September 20). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212306s005lbl.pdf."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1007\/s00018-016-2255-5","article-title":"The recognition of ubiquitinated proteins by the proteasome","volume":"73","author":"Grice","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/abbi.2000.2036","article-title":"Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex","volume":"383","author":"Orlowski","year":"2000","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2183\/pjab.85.12","article-title":"The proteasome: Overview of structure and functions","volume":"85","author":"Tanaka","year":"2009","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"ref_142","unstructured":"NINLARO (Ixazomib) (2021, September 21). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/208462lbl.pdf."},{"key":"ref_143","unstructured":"KYPROLIS (Carfilzomib) (2021, September 21). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/202714s030lbl.pdf."},{"key":"ref_144","first-page":"217","article-title":"Spotlight on ixazomib: Potential in the treatment of multiple myeloma","volume":"10","author":"Muz","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1517\/13543784.2015.1065250","article-title":"Ixazomib for the treatment of multiple myeloma","volume":"24","author":"Gentile","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1016\/j.bmcl.2018.06.044","article-title":"Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead","volume":"28","author":"Martino","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00280-012-2042-4","article-title":"Marqibo\u00ae (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine","volume":"71","author":"Silverman","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s40265-019-01188-9","article-title":"Selinexor: First global approval","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"key":"ref_150","unstructured":"European Medicines Agency (2021, December 02). NEXPOVIO (Selinexor). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/nexpovio-epar-medicine-overview_en-1.pdf."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","article-title":"Venetoclax: First global approval","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"key":"ref_152","unstructured":"European Medicines Agency (2021, December 02). VENCLYXTO (Venetoclax). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/venclyxto-epar-medicine-overview_en.pdf."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40265-016-0548-5","article-title":"Ixazomib: First global approval","volume":"76","author":"Shirley","year":"2016","journal-title":"Drugs"},{"key":"ref_154","unstructured":"European Medicines Agency (2021, December 02). NINLARO (Ixazomib). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/ninlaro-epar-summary-public_en.pdf."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0076-6879(05)91002-1","article-title":"Preparation, characterization, and biological analysis of liposomal formulations of vincristine","volume":"391","author":"Waterhouse","year":"2005","journal-title":"Methods Enzymol."},{"key":"ref_156","first-page":"3479","article-title":"Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: Liposome-encapsulated vincristine","volume":"8","author":"Davis","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"ref_157","unstructured":"European Medicines Agency (2021, December 02). MARQIBO (Vincristine Sulfate LIPOSOME Injection). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/08\/555-public-summary-positive-opinion-orphan-designation-vincristine-sulphate-liposomes-treatment_en.pdf."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"Food and drug administration approval: Carfilzomib for the treatment of multiple myeloma","volume":"19","author":"Herndon","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_159","unstructured":"European Medicines Agency (2021, December 02). KYPROLIS (Carfilzomib). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/kyprolis-epar-medicine-overview_en.pdf."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Clark, D., Pazdernik, N., and McGehee, M. (2019). Chapter 13\u2014Protein synthesis. Molecular Biology, Elsevier. [3rd ed.].","DOI":"10.1016\/B978-0-12-813288-3.00013-6"},{"key":"ref_161","unstructured":"SYNRIBO (Omacetaxine Mepesuccinate) (2021, September 24). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203585s005lbl.pdf."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1517\/14656566.2011.613378","article-title":"Omacetaxine mepesuccinate for the treatment of leukemia","volume":"12","author":"Kim","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_163","first-page":"177","article-title":"Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia","volume":"7","author":"Chen","year":"2014","journal-title":"OncoTargets Ther."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1634\/theoncologist.2013-0077","article-title":"Food and Drug Administration approval summary: Omacetaxine mepesuccinate as treatment for chronic myeloid leukemia","volume":"19","author":"Alvandi","year":"2014","journal-title":"Oncologist"},{"key":"ref_165","unstructured":"U.S. Food and Drug Administration (2021, December 02). NDA 203585Orig1s000, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203585Orig1s000SumR.pdf."},{"key":"ref_166","first-page":"108","article-title":"On the paradoxically concentration-dependent metabolism of 6-mercaptopurine in WEHI-3b murine leukemia cells","volume":"50","author":"Liliemark","year":"1990","journal-title":"Cancer Res."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00280-018-3525-8","article-title":"Role of TPMT and ITPA variants in mercaptopurine disposition","volume":"81","author":"Gerbek","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/0006-2952(93)90045-X","article-title":"6-Mercaptopurine: Cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts","volume":"45","author":"Stet","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/apt.13559","article-title":"Review article: Recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease","volume":"43","author":"Moon","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_170","unstructured":"PURIXAN (Mercaptopurine) (2021, September 27). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205919s000lbl.pdf."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1177\/0091270011423663","article-title":"A step toward more accurate dosing for mercaptopurine in childhood acute lymphoblastic leukemia","volume":"52","author":"Mulla","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1517\/21678707.2015.1022530","article-title":"Orphan drug approvals of 2014: Europe and the United States","volume":"3","author":"Norman","year":"2015","journal-title":"Expert Opin. Orphan Drugs"},{"key":"ref_173","unstructured":"European Medicines Agency (2021, December 02). XALUPRINE (Mercaptopurine). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/xaluprine-epar-summary-public_en.pdf."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00001622-200211000-00008","article-title":"Thalidomide and immunomodulatory drugs as cancer therapy","volume":"14","author":"Raje","year":"2002","journal-title":"Curr. Opin. Oncol."},{"key":"ref_175","unstructured":"POMALYST (Pomalidomide) (2021, September 28). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/204026s024lbl.pdf."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1038\/bcj.2013.38","article-title":"Pomalidomide: The new immunomodulatory agent for the treatment of multiple myeloma","volume":"3","author":"Swaika","year":"2013","journal-title":"Blood Cancer J."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Mendy","year":"2012","journal-title":"Leukemia"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40265-013-0047-x","article-title":"Pomalidomide: First global approval","volume":"73","author":"Elkinson","year":"2013","journal-title":"Drugs"},{"key":"ref_180","unstructured":"European Medicines Agency (2021, December 02). IMNOVID (Pomalidomide). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/imnovid-epar-medicine-overview_en.pdf."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40005-016-0286-4","article-title":"Rationale and strategies for formulation development of oral fixed dose combination drug products","volume":"46","author":"Moon","year":"2016","journal-title":"J. Pharm. Investig."},{"key":"ref_182","unstructured":"Mohapatra, S., Ranjan, S., Dasgupta, N., Mishra, R., and Thomas, S. (2019). Chapter 9\u2014Nanotechnology toward treating cancer: A comprehensive review. Micro and Nano Technologies, Applications of Targeted Nano Drugs and Delivery Systems, Elsevier."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1871-5125(09)34002-9","article-title":"Chapter 2\u2014Cytarabine","volume":"Volume 34","author":"Brittain","year":"2009","journal-title":"Profiles of Drug Substances, Excipients and Related Methodology"},{"key":"ref_184","unstructured":"(2021, September 29). Cytarabine NDA #016793\u2014Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=016793."},{"key":"ref_185","unstructured":"Dowd, F., Johnson, B., and Mariotti, A. (2017). 36\u2014Antineoplastic drugs. Pharmacology and Therapeutics for Dentistry, Mosby. [7th ed.]."},{"key":"ref_186","unstructured":"(2021, September 29). Cerubidine NDA #050484\u2014Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=050484."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e1414","DOI":"10.1634\/theoncologist.2019-0785","article-title":"EMA review of daunorubicin and cytarabine encapsulated in liposomes (Vyxeos, CPX-351) for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes","volume":"25","author":"Tzogani","year":"2020","journal-title":"Oncologist"},{"key":"ref_189","unstructured":"VYXEOS (Daunorubicin and Cytarabine) (2021, October 04). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209401s000lbl.pdf."},{"key":"ref_190","unstructured":"(2021, October 04). Decitabine NDA #021790\u2014Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=021790."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1080\/10428190701471981","article-title":"Decitabine and its role in the treatment of hematopoietic malignancies","volume":"48","author":"Plimack","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_192","unstructured":"INQOVI (Decitabine and Cedazuridine) (2021, October 04). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212576s000lbl.pdf."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s40265-020-01389-7","article-title":"Decitabine\/Cedazuridine: First approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1158\/1078-0432.CCR-18-2990","article-title":"FDA approval summary: (Daunorubicin and Cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia","volume":"25","author":"Krauss","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_195","unstructured":"European Medicines Agency (2021, December 02). VYXEOS (Daunorubicin and Cytarabine), Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/vyxeos-liposomal-epar-medicine-overview_en.pdf."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"150927","DOI":"10.1016\/j.soncn.2019.08.006","article-title":"An overview of monoclonal antibodies","volume":"35","author":"Bayer","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Zahavi, D., and Weiner, L. (2020). Monoclonal antibodies in cancer therapy. Antibodies, 9.","DOI":"10.3390\/antib9030034"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: A biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s40265-020-01405-w","article-title":"Tafasitamab: First approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"ref_200","unstructured":"MONJUVI (Tafasitamab-cxix) (2021, October 07). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761163s000lbl.pdf."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/intimm\/dxh009","article-title":"Mouse CD20 expression and function","volume":"16","author":"Uchida","year":"2004","journal-title":"Int. Immunol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2010-09-305847","article-title":"Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I\/II distinction of CD20 antibodies","volume":"118","author":"Niederfellner","year":"2011","journal-title":"Blood"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Moser","year":"2010","journal-title":"Blood"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_205","unstructured":"TRUXIMA (Rituximab-abbs) (2021, October 08). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761088s000lbl.pdf."},{"key":"ref_206","unstructured":"RUXIENCE (Rituximab-pvvr) (2021, October 08). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761103s000lbl.pdf."},{"key":"ref_207","unstructured":"RIABNI (Rituximab-arrx) (2021, October 08). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761140s000lbl.pdf."},{"key":"ref_208","unstructured":"GAZYVA (Obinutuzumab) (2021, October 08). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125486s017s018lbl.pdf."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nm1101-1209","article-title":"Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo","volume":"7","author":"Cockayne","year":"2001","journal-title":"Nat. Med."},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Martin, T.G., Corzo, K., Chiron, M., van de Velde, H., Abbadessa, G., Campana, F., Solanki, M., Meng, R., Lee, H., and Wiederschain, D. (2019). Therapeutic opportunities with pharmacological inhibition of CD38 with Isatuximab. Cells, 8.","DOI":"10.3390\/cells8121522"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: Mechanisms of action and modes of resistance","volume":"9","author":"Usmani","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/14712598.2021.1841747","article-title":"Isatuximab for the treatment of relapsed\/refractory multiple myeloma","volume":"20","author":"Richardson","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_213","unstructured":"DARZALEX (Daratumumab) (2021, October 11). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761036s035lbl.pdf."},{"key":"ref_214","unstructured":"SARCLISA (Isatuximab-irfc) (2021, October 11). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761113s003lbl.pdf."},{"key":"ref_215","unstructured":"DARZALEX FASPRO (Daratumumab and Hyaluronidase-fihj) (2021, October 11). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761145s002lbl.pdf."},{"key":"ref_216","first-page":"1637","article-title":"CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma","volume":"7","author":"Malaer","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/2040620716652862","article-title":"Elotuzumab: The first approved monoclonal antibody for multiple myeloma treatment","volume":"7","author":"Magen","year":"2016","journal-title":"Ther. Adv. Hematol."},{"key":"ref_218","unstructured":"EMPLICITI (Elotuzumab) (2021, October 12). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761035s008lbl.pdf."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"851","DOI":"10.5858\/arpa.2016-0361-RA","article-title":"Programmed death ligand-1 (PD-L1) expression in the programmed death receptor-1 (PD-1)\/PD-L1 blockade: A key player against various cancers","volume":"141","author":"Guan","year":"2017","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.seminoncol.2017.06.007","article-title":"Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable","volume":"44","author":"Prasad","year":"2017","journal-title":"Semin. Oncol."},{"key":"ref_221","unstructured":"OPDIVO (Nivolumab) (2021, October 15). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125554s058lbl.pdf."},{"key":"ref_222","unstructured":"KEYTRUDA (Pembrolizumab) (2021, October 15). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125514s096lbl.pdf."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/jid.2009.45","article-title":"Cutaneous T-cell lymphoma: Roles for chemokines and chemokine receptors","volume":"129","author":"Wu","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_224","first-page":"883","article-title":"Mogamulizumab-kpkc: A novel therapy for the treatment of cutaneous T-cell lymphoma","volume":"10","author":"Watson","year":"2019","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_225","unstructured":"(2021, December 02). European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/minjuvi-epar-medicine-overview_en.pdf."},{"key":"ref_226","first-page":"1","article-title":"Therapeutic monoclonal antibodies approved by FDA in 2020","volume":"4","author":"Cai","year":"2021","journal-title":"Clin. Res. Immunol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s40265-020-01311-1","article-title":"Isatuximab: First approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_228","unstructured":"European Medicines Agency (2021, December 02). SARCLISA (Isatuximab-irfc). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/sarclisa-epar-medicine-overview_en.pdf."},{"key":"ref_229","unstructured":"European Medicines Agency (2021, December 02). RUXIENCE (Rituximab-pvvr). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/ruxience-epar-medicine-overview_en.pdf."},{"key":"ref_230","unstructured":"U.S. Food and Drug Administration (2021, September 10). FDA Approves First Biosimilar for Treatment of Adult Patients with Non-Hodgkin\u2019s Lymphoma, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-biosimilar-treatment-adult-patients-non-hodgkins-lymphoma."},{"key":"ref_231","unstructured":"European Medicines Agency (2021, December 02). TRUXIMA (Rituximab-Abbs). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/truxima-epar-medicine-overview_en.pdf."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1158\/1078-0432.CCR-19-2030","article-title":"FDA approval summary: Mogamulizumab-kpkc for mycosis fungoides and S\u00e9zary syndrome","volume":"25","author":"Kasamon","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_233","unstructured":"European Medicines Agency (2021, December 02). POTELIGEO (Mogamulizumab-Kpkc). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/poteligeo-epar-medicine-overview_en.pdf."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40265-016-0540-0","article-title":"Elotuzumab: First global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"ref_235","unstructured":"European Medicines Agency (2021, December 02). EMPLICITI (Elotuzumab). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/empliciti-epar-medicine-overview_en.pdf."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-015-0536-1","article-title":"Daratumumab: First global approval","volume":"76","author":"McKeage","year":"2016","journal-title":"Drugs"},{"key":"ref_237","unstructured":"European Medicines Agency (2021, December 02). DARZALEX (Daratumumab). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/darzalex-epar-medicine-overview_en.pdf."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-16-0712","article-title":"FDA approval summary: Nivolumab for treatment of unresectable or metastatic melanoma following progression on Ipilimumab","volume":"23","author":"Hazarika","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_239","unstructured":"OPDIVO (Nivolumab) (2021, November 29). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125554s019lbl.pdf."},{"key":"ref_240","unstructured":"European Medicines Agency (2021, December 02). OPDIVO (Nivolumab). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/opdivo-epar-medicine-overview_en.pdf."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s40265-014-0314-5","article-title":"Pembrolizumab: First global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"ref_242","unstructured":"U.S. Food and Drug Administration (2021, September 10). FDA Approves Pembrolizumab for Treatment of Relapsed or Refractory PMBCL, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-treatment-relapsed-or-refractory-pmbcl."},{"key":"ref_243","unstructured":"U.S. Food and Drug Administration (2021, September 10). Pembrolizumab (KEYTRUDA) for Classical Hodgkin Lymphoma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/pembrolizumab-keytruda-classical-hodgkin-lymphoma."},{"key":"ref_244","unstructured":"European Medicines Agency (2021, December 02). KEYTRUDA (Pembrolizumab). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/keytruda-epar-medicine-overview_en.pdf."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40265-013-0167-3","article-title":"Obinutuzumab: First global approval","volume":"74","author":"Cameron","year":"2014","journal-title":"Drugs"},{"key":"ref_246","unstructured":"European Medicines Agency (2021, December 02). GAZYVARO (Obinutuzumab). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/gazyvaro-epar-summary-public_en.pdf."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0167-5699(00)01659-5","article-title":"Immunotherapeutic perspective for bispecific antibodies","volume":"21","year":"2000","journal-title":"Immunol. Today"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/1078155215618770","article-title":"A review of blinatumomab, a novel immunotherapy","volume":"22","author":"Newman","year":"2016","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40265-015-0356-3","article-title":"Blinatumomab: First global approval","volume":"75","author":"Sanford","year":"2015","journal-title":"Drugs"},{"key":"ref_250","unstructured":"European Medicines Agency (2021, December 02). BLINCYTO (Blinatumomab). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/blincyto-epar-medicine-overview_en.pdf."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jcp.28967","article-title":"Potential drugs used in the antibody\u2013drug conjugate (ADC) architecture for cancer therapy","volume":"235","author":"Yaghoubi","year":"2019","journal-title":"J. Cell Physiol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1074-7613(00)80270-8","article-title":"CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: Altered signaling in CD22-deficient mice","volume":"5","author":"Sato","year":"1996","journal-title":"Immunity"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.molimm.2014.09.014","article-title":"Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies","volume":"67 Pt A","author":"Shor","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/leu.2017.187","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia","volume":"31","author":"Godwin","year":"2017","journal-title":"Leukemia"},{"key":"ref_255","unstructured":"BESPONSA (Inotuzumab Ozogamicin) (2021, October 13). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761040s000lbl.pdf."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-017-0533-9","article-title":"The role of B cell antigen receptors in mantle cell lymphoma","volume":"10","author":"Fichtner","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11899-020-00572-7","article-title":"Polatuzumab Vedotin: A new target for B cell malignancies","volume":"15","author":"Choi","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_260","unstructured":"ADCETRIS (Brentuximab Vedotin) (2021, October 18). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125388s097lbl.pdf."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/bloodadvances.2019000123","article-title":"Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma","volume":"3","author":"Picardi","year":"2019","journal-title":"Blood Adv."},{"key":"ref_262","unstructured":"POLIVY (Polatuzumab Vedotin-Piiq) (2021, October 18). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761121s000lbl.pdf."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: Potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_264","unstructured":"BLENREP (Belantamab Mafodotin-Blmf) (2021, October 18). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761158s000lbl.pdf."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s40265-020-01404-x","article-title":"Belantamab Mafodotin: First approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"ref_266","unstructured":"European Medicines Agency (2021, December 02). BLENREP (Belantamab Mafodotin-Blmf). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/blenrep-epar-medicine-overview_en.pdf."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s40265-019-01175-0","article-title":"Polatuzumab Vedotin: First global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"ref_268","unstructured":"European Medicines Agency (2021, December 02). POLIVY (Polatuzumab Vedotin-piiq). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/polivy-epar-medicine-overview_en.pdf."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s40265-017-0802-5","article-title":"Inotuzumab Ozogamicin: First global approval","volume":"77","author":"Lamb","year":"2017","journal-title":"Drugs"},{"key":"ref_270","unstructured":"European Medicines Agency (2021, December 02). BESPONSA (Inotuzumab Ozogamicin). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/besponsa-epar-summary-public_en.pdf."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1158\/1078-0432.CCR-12-1803","article-title":"Food and Drug Administration approval summary: Brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma","volume":"18","author":"McGinn","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_272","unstructured":"European Medicines Agency (2021, December 02). ADCETRIS (Brentuximab Vedotin). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/adcetris-epar-medicine-overview_en.pdf."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S0952-7915(99)00005-9","article-title":"Immunotoxins in cancer therapy","volume":"11","author":"Kreitman","year":"1999","journal-title":"Curr. Opin. Immunol."},{"key":"ref_274","unstructured":"LUMOXITI (Moxetumomab Pasudotox-Tdfk) (2021, October 19). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761104s000lbl.pdf."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-11-0487","article-title":"Antibody fusion proteins: Anti-CD22 recombinant immunotoxin moxetumomab pasudotox","volume":"17","author":"Kreitman","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-018-1000-9","article-title":"Moxetumomab Pasudotox: First global approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"ref_277","unstructured":"European Medicines Agency (2021, December 02). LUMOXITI (Moxetumomab Pasudotox-tdfk). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/lumoxiti-epar-medicine-overview_en.pdf."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"582587","DOI":"10.3389\/fphar.2020.582587","article-title":"Amino acid degrading enzymes and autophagy in cancer therapy","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/nyas.12496","article-title":"Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia","volume":"1329","author":"Salzer","year":"2014","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1158\/1078-0432.CCR-19-1255","article-title":"FDA approval summary: Calaspargase Pegol-mknl For treatment of acute lymphoblastic leukemia in children and young adults","volume":"26","author":"Li","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_281","unstructured":"ERWINAZE (Asparaginase Erwinia Chrysanthemi) (2021, October 20). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125359lbl.pdf."},{"key":"ref_282","unstructured":"ASPARLAS (Calaspargase Pegol\u2014mknl) (2021, October 20). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761102s000lbl.pdf."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40259-013-0051-4","article-title":"Asparaginase Erwinia chrysanthemi (Erwinaze\u00ae): A guide to its use in acute lymphoblastic leukemia in the USA","volume":"27","author":"Keating","year":"2013","journal-title":"BioDrugs"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1002\/jps.23570","article-title":"The utility of modeling and simulation in drug development and regulatory review","volume":"102","author":"Huang","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"ref_285","unstructured":"European Medicines Agency (2021, December 01). List of Nationally Authorised Medicinal Products. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/psusa\/asparaginase-crisantaspase-pegaspargase-nationally-authorised-products-list-nationally-authorised\/00003161\/201808_en.pdf."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s11596-019-2118-z","article-title":"CAR T cell therapy for hematological malignancies","volume":"39","author":"Yang","year":"2019","journal-title":"Curr. Med. Sci."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7150\/jca.48976","article-title":"Current progress in CAR-T cell therapy for hematological malignancies","volume":"12","author":"Han","year":"2021","journal-title":"J. Cancer"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical pharmacology of Tisagenlecleucel in B-cell acute lymphoblastic leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_289","unstructured":"KYMRIAH (Tisagenlecleucel) (2021, October 21). Prescribing Information, Available online: https:\/\/www.fda.gov\/media\/107296\/download."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/14712598.2021.1889510","article-title":"Brexucabtagene autoleucel for the treatment of relapsed\/refractory mantle cell lymphoma","volume":"21","author":"Mian","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"2040620720902899","DOI":"10.1177\/2040620720902899","article-title":"Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas","volume":"11","author":"Riedell","year":"2020","journal-title":"Ther. Adv. Hematol."},{"key":"ref_292","unstructured":"YESCARTA (Axicabtagene Ciloleucel) (2021, October 23). Prescribing Information, Available online: https:\/\/www.fda.gov\/media\/108377\/download."},{"key":"ref_293","unstructured":"TECARTUS (Brexucabtagene Autoleucel) (2021, October 23). Prescribing Information, Available online: https:\/\/www.fda.gov\/media\/140409\/download."},{"key":"ref_294","unstructured":"U.S. Food and Drug Administration (2021, October 25). FDA Approves First Cell-Based Gene Therapy For Adult Patients with Relapsed or Refractory MCL, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-cell-based-gene-therapy-adult-patients-relapsed-or-refractory-mcl."},{"key":"ref_295","unstructured":"European Medicines Agency (2021, December 01). TECARTUS (Brexucabtagene Autoleucel). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/tecartus-epar-medicine-overview_en.pdf."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA approval summary: Axicabtagene Ciloleucel for relapsed or refractory large B-cell lymphoma","volume":"25","author":"Bouchkouj","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_297","unstructured":"European Medicines Agency (2021, December 01). YESCARTA (Axicabtagene Ciloleucel). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/yescarta-epar-medicine-overview_en.pdf."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"FDA approval summary: Tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia","volume":"25","author":"Lu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_299","unstructured":"European Medicines Agency (2021, December 01). KYMRIAH (Tisagenlecleucel). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/kymriah-epar-medicine-overview_en.pdf."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"112270","DOI":"10.1016\/j.ejmech.2020.112270","article-title":"Design and discovery of boronic acid drugs","volume":"195","author":"Plescia","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"12290","DOI":"10.1021\/acs.jmedchem.0c00530","article-title":"Amide bond bioisosteres: Strategies, synthesis, and successes","volume":"63","author":"Kumari","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"112679","DOI":"10.1016\/j.ejmech.2020.112679","article-title":"Hydroxamic acid hybrids as the potential anticancer agents: An overview","volume":"205","author":"Liu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF00316585","article-title":"Studies on the mechanism of acute toxicity of nitriles in mice","volume":"55","author":"Tanii","year":"1984","journal-title":"Arch. Toxicol."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0165-1110(83)90034-9","article-title":"Mutagenicity and genotoxicity of nitroarenes. All nitro-containing chemicals were not created equal","volume":"114","author":"Rosenkranz","year":"1983","journal-title":"Mutat. Res."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"7902","DOI":"10.1021\/jm100762r","article-title":"Nitrile-containing pharmaceuticals: Efficacious roles of the nitrile pharmacophore","volume":"53","author":"Fleming","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1021\/acs.jmedchem.8b00147","article-title":"Nitro-Group-Containing Drugs","volume":"62","author":"Nepali","year":"2019","journal-title":"J. Med. Chem."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/1\/87\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:52:58Z","timestamp":1760169178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/1\/87"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,24]]},"references-count":306,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["cancers14010087"],"URL":"https:\/\/doi.org\/10.3390\/cancers14010087","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,24]]}}}